Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease

  • Stephen J. Duffy
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • Elizabeth S. Biegelsen
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • Monika Holbrook
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • Judson D. Russell
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • Noyan Gokce
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • John F. Keaney
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.
  • Joseph A. Vita
    From the Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.

書誌事項

公開日
2001-06-12
DOI
  • 10.1161/01.cir.103.23.2799
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:italic>Background</jats:italic> —Some epidemiological studies have shown that increased iron stores are associated with increased cardiovascular events. Redox-active iron may contribute to lipid peroxidation, endothelial cell activation, and generation of reactive oxygen species (especially hydroxyl radical, via Fenton chemistry). Increased oxidative stress is associated with impaired action of endothelium-derived nitric oxide in patients with atherosclerosis. </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> —To test the hypothesis that reducing vascular iron stores would reverse endothelial dysfunction, we examined the effects of the iron chelator deferoxamine (500 mg intra-arterially over 1 hour) on vasomotor function in forearm resistance vessels of patients with coronary artery disease by venous occlusion plethysmography. Patients with coronary artery disease had impaired endothelium-dependent vasodilation in response to methacholine compared with healthy control subjects ( <jats:italic>P</jats:italic> <0.001). Deferoxamine infusion decreased serum iron levels ( <jats:italic>P</jats:italic> <0.001). Deferoxamine improved the blood flow response to methacholine in patients with coronary artery disease ( <jats:italic>P</jats:italic> <0.01 by 2-way repeated-measures ANOVA) but had no effect on the response to sodium nitroprusside. In normal volunteers, deferoxamine had no effect on the response to methacholine. The nitric oxide synthase inhibitor <jats:italic>N</jats:italic> <jats:sup>G</jats:sup> -monomethyl- <jats:sc>l</jats:sc> -arginine abolished augmentation of the methacholine response associated with deferoxamine. The hydroxyl radical scavenger mannitol had no effect on the methacholine response. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —Deferoxamine improved nitric oxide–mediated, endothelium-dependent vasodilation in patients with coronary artery disease. These results suggest that iron availability contributes to impaired nitric oxide action in atherosclerosis. </jats:p>

収録刊行物

  • Circulation

    Circulation 103 (23), 2799-2804, 2001-06-12

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ